Skip to content
Menu

Synlogic, Inc. SYBX

Full chart Compare
Set alert

Price alert · SYBX

All alert types
0.96 USD -0.02 (-2.42%)

As ofNov 20, 2026, 3:46 PM EST

0.9601 Day range 0.9602
0.56 52-week range 1.67
YTD
-14.27%
1 year
-39.99%

 

No chart data for this range yet.
Market cap
11.76M
Revenue (ttm)
3.17M
EPS (ttm)
0.47
Shares out
11.70M
P/E ratio
2.04
Forward P/E
-2.94
YTD return
-14.27%
1-year return
-39.99%
Volume
3.90K
Avg volume
13.96K
Open
0.9601
Previous close
0.984
Day's range
0.9601 – 0.9602
52-week range
0.56 – 1.67
Beta
0.84
Price target
1.00 (+4.1%)

Key statistics

50-day average
1.42
200-day average
1.57
Enterprise value
-3.47M
Price / sales
5.10
Price / book
0.30
Free cash flow
-15.87M
Total cash
19.97M
Return on equity
-158.75%
Short % of float
1.31%

Fundamental scorecard

6 of 25 checks passed on SYBX’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2025.

Financials — quick view

All financials
SYBX Revenue — quarterly 0
SYBX Net income — quarterly -2.30M
SYBX EPS — quarterly -0.19

Earnings

SYBX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.18-0.01+0.17+94.44%
Aug 8, 2024Jun 1, 2024-0.510.16+0.67+131.37%
May 14, 2024Mar 1, 2024-0.80-2.60-1.80-225.00%
Mar 19, 2024Dec 1, 2023-1.11-1.71-0.60-54.05%
Nov 9, 2023Sep 1, 2023-2.55-2.57-0.02-0.78%
Aug 10, 2023Jun 1, 2023-3.90-3.15+0.75+19.23%

Upgrades / downgrades

SYBX analyst upgrades and downgrades
DateFirmActionFromTo
Mar 20, 2024HC Wainwright & Co.upSellNeutral
Feb 9, 2024Chardan CapitaldownBuyNeutral
Feb 9, 2024Leerink PartnersdownOutperformMarket Perform
Feb 9, 2024HC Wainwright & Co.downBuySell
Dec 11, 2023Alliance Global Partnersinit—Buy

About Synlogic, Inc.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on SYBX — it syncs with the Stock Master app.

Insider holders

SYBX insider holders
InsiderRelationLatest transactionDateShares held
AWAD ANTOINEChief Operating OfficerSaleApr 1, 202433,859
BRENNAN AOIFE MChief Executive OfficerSaleApr 2, 2023256,301
DOOLEY MARY BETHOfficerSaleOct 28, 202415,152
JENSEN MICHAEL VANGSTEDChief Financial OfficerSaleApr 2, 202346,947

Institution ownership

SYBX institution ownership
Holder% heldSharesValueReported
Cable Car Capital LLC 28.32%3,312,2194.58MSep 29, 2024
NEA Management Company, LLC24.99%2,922,7724.04MSep 29, 2024
Vanguard Group Inc1.56%183,002252.85KSep 29, 2024
FMR, LLC1.43%166,724230.36KSep 29, 2024
Renaissance Technologies, LLC0.61%71,92899.38KSep 29, 2024
Geode Capital Management, LLC0.55%64,23488.75KSep 29, 2024

Fund ownership

SYBX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.19%139,449192.68KSep 29, 2024
Variable Insurance Products Fund-Growth Portfolio0.66%76,833106.16KOct 30, 2024
Fidelity Advisor Equity Growth Fund0.37%43,11659.57KOct 30, 2024
Vanguard Extended Market Index Fund0.36%42,47658.69KSep 29, 2024
Fidelity Extended Market Index Fund0.35%41,34157.12KOct 30, 2024
Fidelity Growth Discovery Fund0.25%29,26040.43KOct 30, 2024